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Abstract
Nesfatin-1, a peptide whose receptor is yet to be identified, has been involved in the modulation of 
feeding, stress and metabolic responses. More recently, increasing evidence supports a modulatory 
role for nesfatin-1 in autonomic and cardiovascular activity. This study was undertaken to test if 
the expression of nesfatin-1 in the nucleus ambiguus, a key site for parasympathetic cardiac 
control, may be correlated with a functional role. Since we have previously demonstrated that 
nesfatin-1 elicits Ca2+ signaling in hypothalamic neurons, we first assessed the effect of this 
peptide on cytosolic Ca2+ in cardiac preganglionic neurons of nucleus ambiguus. We provide 
evidence that nesfatin-1 increases cytosolic Ca2+ concentration via a Gi/o-coupled mechanism. 
The nesfatin-1-induced Ca2+ rise is critically dependent on Ca2+ influx via P/Q-type voltage-
activated Ca2+ channels. Repeated administration of nesfatin-1 leads to tachyphylaxis. Further, 
nesfatin produces a dose-dependent depolarization of cardiac vagal neurons via a Gi/o-coupled 
mechanism. In vivo studies, using telemetric and tail-cuff monitoring of heart rate and blood 
pressure, indicate that microinjection of nesfatin-1 into the nucleus ambiguus produces 
bradycardia not accompanied by a change in blood pressure in conscious rats. Taken together, our 
results identify for the first time that nesfatin-1 decreases heart rate by activating cardiac vagal 
neurons of nucleus ambiguus.
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Introduction
Nesfatin-1, an 82 amino acid cleavage product of nucleobindin-2 protein, has been described 
as a central and peripheral satiety molecule that induces acute and chronic anorexigenic 
effects (Oh-I et al. 2006, Maejima et al. 2009). Its widespread distribution throughout the 
brain (Brailoiu et al. 2007, Goebel et al. 2009) and the periphery (Palasz et al. 2012) 
suggests that it may regulate other functions besides feeding. Experimental evidence 
supports the involvement of nesfatin-1 in the modulation of neuroendocrine functions, 
stress, metabolic responses (García-Galiano et al. 2010, Stengel & Taché, 2011).
With respect to the cardiovascular regulation, nesfatin-1 elevates blood pressure and renal 
sympathetic nerve activity upon intracerebroventricular administration in conscious and 
urethane-anesthetized rats (Yosten & Samson 2009, Tanida & Mori 2011). Further, 
nesfatin-1 modulates the excitability of nucleus of the solitary tract neurons and produces 
hypertensive and tachycardic responses upon microinjection at this site (Mimee et al. 2012). 
Direct modulation of peripheral arterial resistance also mediates nesfatin-1-dependent 
pressor effects (Yamawaki et al. 2012). Nesfatin-1 expression in the heart has been 
correlated with negative inotropism and protection against ischemia-reperfusion injury 
(Angelone et al. 2012).
Premotor cardiac vagal neurons of nucleus ambiguus play an essential role in heart rate 
regulation (Mendelowitz, 1999). Since nesfatin-1 immunoreactivity has been detected in 
nucleus ambiguus in rodents (Goebel et al. 2009, Goebel-Stengel et al. 2011), we used in 
vitro and in vivo approaches to examine whether or not nesfatin-1 has a functional role in 
cardiac-projecting neurons of nucleus ambiguus neurons.
Experimental procedures
Chemicals
All chemicals were from Sigma-Aldrich (St. Louis, MO) unless otherwise mentioned.
Animals
Neonatal Sprague-Dawley rats (1–2 days old) (Charles River Laboratories, Wilmington, 
MA) of either sex were used for retrograde tracing and neuronal culture and adult male rats 
were used for telemetric and tail-cuff measurement of heart rate. Protocols were reviewed 
and approved by the Institutional Animal Care and Use Committee.
Neuronal labeling and culture
Preganglionic cardiac vagal neurons of nucleus ambiguus were retrogradely labeled by 
intrapericardial injection of rhodamine [5(6) X-RITC; X-rhodamine-5-(and-6)- 
isothiocyanate] 40 μl, 0.01%, (Invitrogen, Carlsbad, CA), as previously reported (Bouairi et 
al. 2006, Brailoiu et al. 2012, 2013). Medullary neurons were dissociated and cultured 24 h 
after rhodamine injection, as described (Brailoiu et al. 2012, 2013). Briefly, the brains were 
quickly removed and immersed in ice-cold Hanks’ balanced salt solution (HBSS) 
(Mediatech, Manassas, VA). The ventral side of the medulla (containing nucleus ambiguus) 
was dissected, minced, and the cells were dissociated by enzymatic digestion with papain, 
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followed by mechanical trituration. After centrifugation at 500 g, fractions enriched in 
neurons were collected and resuspended in culture medium containing Neurobasal-A 
(Invitrogen), which promotes the survival of postnatal neurons, 1% GlutaMax (Invitrogen), 
2% penicillin–streptomycin–amphotericin B solution (Mediatech), and 10% fetal bovine 
serum (Atlanta Biologicals Inc., Lawrenceville, GA). Cells were plated on round 25 mm 
glass coverslips previously coated with poly-L-lysine in six-well plates. Cultures were 
maintained at 37°C in a humidified atmosphere with 5% CO2. The mitotic inhibitor cytosine 
β-arabino furanoside (1 μM) was added to the culture to inhibit glial cell proliferation 
(Schoniger et al. 2001).
Calcium imaging
Measurements of [Ca2+]i were performed as previously described (Brailoiu et al. 2012, 
2013). Cells were incubated with 5 μM fura-2 AM (Invitrogen, Carlsbad, CA) in HBSS at 
room temperature for 45 min, in the dark, washed three times with dye-free HBSS, and then 
incubated for another 45 min to allow for complete de-esterification of the dye. Coverslips 
(25 mm diameter) were subsequently mounted in an open bath chamber (RP-40LP, Warner 
Instruments, Hamden, CT) on the stage of an inverted microscope Nikon Eclipse TiE (Nikon 
Inc., Melville, NY). The microscope was equipped with a Perfect Focus System and a 
Photometrics CoolSnap HQ2 CCD camera (Photometrics, Tucson, AZ). During the 
experiments the Perfect Focus System was activated. Fura-2 AM fluorescence (emission= 
510 nm), following alternate excitation at 340 and 380 nm, was acquired at a frequency of 
0.25 Hz. Images were acquired and analyzed using NIS-Elements AR 3.1 software (Nikon 
Inc.). The ratio of the fluorescence signals (340/380 nm) was converted to Ca2+ 
concentrations (Grynkiewicz et al. 1985).
Measurement of membrane potential
The relative changes in membrane potential of single neurons were evaluated using bis-(1,3-
dibutylbarbituric acid) trimethine oxonol, DiBAC4(3) (Invitrogen), a slow response voltage-
sensitive dye, as previously described (Brailoiu et al. 2010). Upon membrane 
hyperpolarization, the dye concentrates in the cell membrane, leading to a decrease in 
fluorescence intensity, while depolarization induces the sequestration of the dye into the 
cytosol, resulting in an increase of the fluorescence intensity (Brauner et al. 1984). Cultured 
neurons were incubated for 30 min in HBSS containing 0.5 mM DiBAC4(3) and 
fluorescence monitored at 0.17 Hz (excitation/emission 480nm/540nm). Calibration of 
DiBAC4(3) fluorescence following background subtraction was performed using the Na+-
K+ ionophore gramicidin in Na+-free physiological solution and various concentrations of 
K+ (to alter membrane potential) and N-methylglucamine (to maintain osmolarity) (Brauner 
et al. 1984). Under these conditions the membrane potential is approximately equal to the 
K+ equilibrium potential determined by the Nernst equation. The intracellular K+ and Na+ 
concentration were assumed to be 130 mM and 10 mM, respectively.
Surgical procedures
Male Sprague-Dawley rats (200–250 g) were anesthetized with an intraperitoneal injection 
of a mixture of ketamine hydrochloride (100–150 mg/kg) and acepromazine maleate (0.2 
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mg/kg). Animals were placed into a stereotaxic instrument; a guide C315G cannula 
(PlasticsOne, Roanoke, VA) was bilaterally inserted into the nucleus ambiguus and fixed in 
position with dental cement. The stereotaxic coordinates for identification of nucleus 
ambiguus were: 12.24 mm posterior to bregma, 2.1 mm from the midline and 8.2 mm 
ventral to the dura mater (Paxinos & Watson, 1998). A C315DC cannula dummy 
(PlasticsOne) of identical length was inserted into the guide cannula to prevent any 
contamination. For the implantation of transmitters, an incision 2 cm in length was made 
along the linea alba, and the underlying tissue was dissected and retracted. A calibrated 
transmitter (E-mitters, series 4000; Mini Mitter, Sunriver, OR) was inserted in the 
intraperitoneal space, as previously described (Benamar et al. 2010). After the transmitter 
was passed through the incision, the abdominal musculature and dermis were sutured 
independently and the animals were returned to individual cages. The animals were 
observed daily to ensure health and recovery.
Telemetric heart rate monitoring
The signal generated by transmitters was collected via series 4000 receivers (Mini Mitter, 
Sunriver, OR) placed underneath the home cage. VitalView™ software (Mini Mitter, 
Sunriver, OR) was used for data acquisition. Each data point represents the average of heart 
rate per 1 min.
Non-invasive blood pressure measurement
In rats with cannula inserted into the nucleus ambiguus, blood pressure was non-invasively 
measured by determining the tail blood volume with a volume pressure recording sensor and 
an occlusion tail-cuff (CODA System, Kent Scientific, Torrington, CT). The nose cone was 
custom modified to allow access to the cannula. One week after the insertion of the cannula, 
rats were exposed to handling and training every day for 1 week, starting with 25 minutes in 
the first day of handling and training in the room where measurements were to be taken and 
progressively increasing the time to 1 h in the day seven (Fraser et al. 2001; Feng et al. 
2008). The maximum occlusion pressure was 200 mm Hg, minimum volume 30 mm Hg and 
deflation time 10 seconds. Three measurements were done per minute (one cycle) and the 
average was used to calculate heart rate, systolic and diastolic blood pressure as well as 
mean arterial pressure. Ten acclimatization cycles were done before starting the 
experiments.
Microinjection into nucleus ambiguus
One week after surgery (telemetry studies) or after another week of training (tail-cuff 
measurements), either vehicle, L-glutamate or nesfatin-1 was bilaterally microinjected into 
the nucleus ambiguus, using the C315I internal cannula (33 gauge, PlasticsOne), without 
handling the rats (telemetric measurement). In case of the tail-cuff method, trained rats were 
in the animal holder for the duration of the experiment. Handling the rats induced a robust 
increase in heart rate in the absence of any treatments (McDouglas et al. 2004). For 
recovery, at least two hours were allowed between two injections. Injection of L-glutamate 
(5 mM, 50 nL with Neuros Hamilton syringe, Model 7000.5 KH SYR) was used for the 
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functional identification of nucleus ambiguus (Chitravanshi et al. 2009; Brailoiu et al. 
2013).
Histology
Typical sites of cannula placement in the nucleus ambiguus were marked by microinjections 
of diluted (1:42) green Lumafluor retrobeads (Lumafluor Inc., Durham, NC) as previously 
reported (Brailoiu et al. 2013). Rats were perfused and fixed with 4% paraformaldehyde. 
Serial sections of the medulla were cut (30–40 μm), mounted on slides, covered with 
Vectashield mounting medium (Vector Laboratories, Burlingame, CA) and coverslipped. 
The microinjection sites were identified using a fluorescence microscope, photographed and 
compared with a standard rat brain atlas (Paxinos & Watson, 1998).
Statistical analysis
Data were expressed as mean ± standard error of mean. One-way ANOVA followed by post 
hoc analysis using Bonferonni and Tukey tests was used to evaluate significant differences 
between groups.
Results
Nesfatin-1 elevates cytosolic Ca2+ in cardiac preganglionic neurons of nucleus ambiguus
Nesfatin-1 (10−6M) produced a robust increase in [Ca2+]i in rhodamine-labeled cardiac-
projecting neurons of nucleus ambiguus: the Ca2+ response was characterized by a fast 
increase followed by a plateau lasting 2–3 min (Fig. 1A). The nesfatin-1-induced Ca2+ 
response returned to basal levels within 4 min. Nesfatin (10−8, 10−7, 10−6 and 10−5 M) 
produced an increase in [Ca2+]i by 32 ± 1.7 nM, 271 ± 3.9 nM, 367 ± 4.3 nM, and 376 ± 4.9 
nM, respectively (n = 6 for each concentration tested) (Fig. 1B); statistical significance (P < 
0.05) was attained for the higher doses of nesfatin (10−7, 10−6 and 10−5M). The increase in 
[Ca2+]i produced by the highest concentration of nesfatin (10−5 M) tested was not 
statistically different from that produced by nesfatin 10−6 M (Fig. 1B). Pretreatment with the 
oxytocin receptor antagonist L-371,257 (10−7M) (Kuo et al., 1998) or with the antagonist of 
melanocortin receptors type 3/4, SHU 9119 (10−7 M) (Tanida & Mori, 2011), did not 
significantly affect the increase in [Ca2+]i produced bynesfatin-1 (10−6M): Δ[Ca2+]i = 376 ± 
4.9 nM in the absence of the antagonists, vs 358 ± 6.3 nM in the presence of L-371,257 or 
349 ± 5.7 nM in the presence of SHU 9119 (n = 6 for each treatment) (Fig. 1B).
Repeated administration of nesfatin-1 produces tachyphylaxis
In this series of experiments, cardiac vagal neurons of nucleus ambiguus were treated with 
nesfatin-1 twice, while monitoring the Ca2+ response. The second application of nesfatin-1, 
after Ca2+ returned to the basal values following the first response, produced an increase in 
[Ca2+]i with a lower amplitude than the first application (Fig. 2). Representative images of 
fluorescence 340/380 ratio of a rhodamine-labeled neuron treated twice with nesfatin-1 
(10−6 M) are shown in Fig 2A, and examples of individual Ca2+ responses after two 
treatments with nesfatin-1 are shown in Fig. 2C. As illustrated in Fig. 2D, the initial 
application of nesfatin-1 (10−6 M) increased [Ca2+]i by 354 ± 4.6 nM (n = 6), while the Ca2+ 
response to the subsequent application was significantly reduced to 142 ± 2.8 nM (P < 0.05, 
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n = 6), indicating tachyphylaxis. We have previously shown that urocortin 3 activates 
nucleus ambiguus neurons (Brailoiu et al. 2012). We tested if the response to urocortin 3 
was affected by previous treatment with nesfatin-1. When the cells were treated with 
urocortin 3 after recovering to the basal level after the nesfatin-1 application, the response to 
urocortin 3 was not affected (Fig. 2B, C) and similar to that previously reported (Brailoiu et 
al. 2012).
Nesfatin-1 effects are mediated by a Gi/o-coupled mechanism in nucleus ambiguus 
neurons
The Ca2+ response of cardiac vagal neurons to nesfatin-1 (10−6 M) was markedly reduced 
by inhibition of Gi/o proteins with pertussis toxin (PTX, 100 nM): Δ[Ca2+]i = 38 ± 3.4 nM 
after pertussis toxin (n = 6, P < 0.05), as compared to Δ[Ca2+]i = 367 ± 4.3 nM, in the 
absence of the pertussis toxin. On the other hand, incubation with cholera toxin (CTX, 100 
nM), that blocks Gs-dependent signaling, did not affect the nesfatin-1 induced increase in 
[Ca2+]i (3 [Ca2+]i was 367 ± 5.1 nM, n = 6 in presence of CTX vs 367 ± 4.3 nM upon 
treatment with nesfatin-1 alone) (Fig. 3A, B).
Nesfatin-1-induced Ca2+ elevation is contingent on Ca2+ influx via voltage-gated P/Q 
channels
Nesfatin-1(10−6 M) -induced increase in [Ca2+]i was abolished when cardiac preganglionic 
neurons of nucleus ambiguus were incubated with Ca2+-free saline (Δ [Ca2+]i = 5 ± 1.3 nM, 
n = 6), indicating that its effect on [Ca2+]i is dependent on Ca2+ influx via plasmalemmal 
Ca2+ channels. Using selective Ca2+ channels blockers, we evaluated the contribution of 
different types of voltage-gated Ca2+ channels to nesfatin effects. In the presence of 
nifedipine (1 μM), a L-type Ca2+ channel inhibitor, or –conotoxin GVIA (100 nM), a 
blocker of N-type Ca2+ channels, nesfatin-1 (10−6 M) elevated [Ca2+]i by 359 ± 5.2 nM (n = 
6) and 344 ± 4.8 nM (n = 6), respectively, responses largely resembling that produced in 
absence of any blocker (Δ [Ca2+]i = 367 ± 4.3 nM, Fig. 4A, B). However, preventing Ca2+ 
influx via P/Q-type Ca2+ channels with –conotoxin MVIIC (100 nM) basically abolished the 
effect of nesfatin (Δ [Ca2+]i =19 ± 2.6 nM, n = 6, Fig. 4A, B).
Nesfatin-1 depolarizes cardiac vagal neurons of nucleus ambiguus
Cultured vagal preganglionic neurons had a mean resting potential of −55.75 ± 0.05 mV (n 
= 24), as previously reported using classical electrophysiological techniques in brain stem 
slices (Brailoiu et al. 2013) or cultured neurons (Mendelowitz and Kunze, 1991), or by using 
voltage imaging in cultured neurons (Brailoiu et al., 2012). Administration of nesfatin-1 
resulted in a rapid membrane depolarization, which declined gradually and receded within 4 
min; a representative recording is shown in Fig. 5A. The effect of nesfatin-1 on membrane 
potential was sensitive to Gi/o protein blockade with pertussis toxin. Increasing 
concentrations of nesfatin-1 (10−8, 10−7, 10−6 and 10−5M) depolarized cardiac preganglionic 
neurons by 0.51 ± 0.16 mV, 3.97 ± 0.28 mV, 6.34 ± 0.47 mV, and 6.53 ± 0.54 (n = 6 for 
each concentration), respectively (Fig. 5B). Depolarizations induced by 10−7, 10−6 and 
10−5M nesfatin-1 were statistically significant (P < 0.05), as compared to the resting 
membrane potential. The amplitude of the depolarization induced by the highest 
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concentration of nesfatin tested (10−5M) was not statistically different from that produced by 
nesfatin 10−6 M (P > 0.05). Pretreatment with pertussis toxin (PTX, 100 nM), abolished the 
depolarization induced by 10−6 M nesfatin-1 (0.82 ± 0.63 mV, n = 6, Fig. 5B), supporting 
the Gi/o-dependency of the response.
Microinjection of nesfatin-1 into nucleus ambiguus decreases the heart rate in awake rats
In conscious, freely moving rats, bearing cannula implanted into nucleus ambiguus, 
microinjection of nesfatin-1 (5 pmol) produced a decrease in heart rate; a representative 
example is shown in Fig. 6A. Microinjection of L-glutamate (L-Glu, 5 mM) into the nucleus 
ambiguus elicited a bradycardic response (Fig. 6A) as previously reported, indicating the 
correct placement of cannula (Chitravanshi et al. 2009, 2012; Brailoiu et al., 2013). 
Microinjection of L-glutamate (5 mM, 50 nl) into the nucleus ambiguus reduced the heart 
rate by 83 ± 6 beats per minutes (n = 5). Microinjection of nesfatin-1 (0.05, 0.5 and 5 pmol), 
2 h after L-glutamate, elicited a dose-dependent decrease in heart rate by 7 ± 3, 29 ± 4 and 
41 ± 5 beats per min, respectively (n= 5 rats for each dose tested) (Fig. 6B).
To verify whether or not the microinjection of nesfatin-1 in nucleus ambiguus was 
associated with any change in blood pressure, the blood pressure was monitored by tail-cuff 
method in rats with a cannula inserted in the nucleus ambiguus after one week of training. 
Microinjection of L-glutamate and nesfatin-1 into the nucleus ambiguus produced 
bradycardic responses that were not accompanied by changes in blood pressure; 
representative examples of recordings are shown in Fig. 6A. Microinjection of L-glutamate 
(5 mM, 50 nl) decreased the heart rate by 84 ± 4 beats per min and microinjection of 
nesfatin-1 (5 pmol) decreased the heart rate by 42 ± 4 beats per min (n = 5). (Fig. 6B); these 
values are similar to those obtained by telemetric measurement. The excellent correlation 
between the two methods is in agreement with previous studies (Fraser et al. 2001; Feng et 
al. 2008).
Discussion
Emerging evidence supports a broad range of regulatory roles for nesfatin-1 in addition to 
the initial reported role on feeding behavior (Oh-I et al. 2006; García-Galiano et al. 2010, 
Stengel & Taché, 2011). Nesfatin-1 expression in the nucleus ambiguus has been 
documented relatively recent (Goebel et al. 2009; Goebel-Stengel et al., 2011). Given the 
key role of nucleus ambiguus in the autonomic cardiac regulation (Mendelowitz, 1999), we 
sought experimental evidence of a functional role of nesfatin-1 in cardiac-projecting neurons 
of nucleus ambiguus. Since we have previously found that nesfatin-1 elicits calcium 
signaling in neurons (Brailoiu et al. 2007), we first used calcium imaging to test the 
responsiveness of cardiac preganglionic neurons of nucleus ambiguus to nesfatin-1.
Treatment of cardiac vagal neurons with nesfatin-1 induced a rapid and dose-dependent rise 
in [Ca2+]i in cardiac preganglionic neurons of nucleus ambiguus. The response pattern was 
similar to that identified in hypothalamic neurons (Brailoiu et al.2007), and likely indicative 
of interaction with a G protein-coupled receptor. The amplitude of the Ca2+ response 
triggered by a second application of nesfatin-1 was lower than that of the first. This 
tachyphylactic response suggests receptor desensitization, a common phenomenon among G 
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protein-coupled receptors (Gainetdinov et al. 2004). However, tachyphylaxis did not occur, 
when nucleus ambiguus neurons were treated with urocortin 3 following the treatment with 
nesfatin-1. This may indicate the lack of heterologous sensitization between CRF2 receptor, 
responsible for the Ca2+ response to urocortin 3 in nucleus ambiguus (Brailoiu et al. 2012), 
and the nesfatin-1 receptor.
While evidence of a specific nesfatin-1 receptor is lacking, studies with pharmacological 
antagonists suggest that the melanocortin system (Oh-I et al. 2006; Yosten & Samson 2009; 
Tanida & Mori 2011) or oxytocin system (Yosten & Samson 2010) play a role in the neural 
circuitry mediating the effects of nesfatin-1. For example, prior administration of the 
antagonist of the melanocortin receptor type 3/4, SHU9119 (Adan et al. 1999), eliminated 
the nesfatin-1-induced satiety in rats (Oh-I et al. 2006). However, treatment with the 
melanocortin receptor type 3/4 antagonist, SHU9110, or with the oxytoxin receptor 
antagonist L-371,257 did not affect the nesfatin-1-induced increase in cytosolic Ca2+ in 
nucleus ambiguus neurons. Since the ability of oxytocin or melanocortin antagonists to 
block the effects of nesfatin-1 has been attributed to the sympatho-stimulatory action of the 
peptide in the nucleus of the tractus solitarius (NTS), the lack of effect of the antagonists 
noted here is not surprising.
We have previously demonstrated that in hypothalamic neurons, nesfatin-1-dependent Ca2+ 
response is pertussis toxin-sensitive, thus coupled with Gi/o proteins. In hypothalamic 
neurons, the effect was also depended on protein kinase A (Brailoiu et al. 2007), which is 
largely activated via Gs proteins, indicating that nesfatin-1 receptor may switch coupling 
between the two types of G proteins (Daaka et al. 1997). However, this is not the case in 
neurons of nucleus ambiguus examined in the current study, as the nesfatin-1-induced 
elevation of cystosolic Ca2+ was not sensitive to cholera toxin, an inhibitor of Gs-dependent 
signaling, but only to the Gi/o blocker pertussis toxin.
In an additional series of experiments we sought to identify the source of Ca2+ mobilized by 
nesfatin-1. In the absence of extracellular Ca2+, nesfatin-1 did not elicit a Ca2+ response in 
cardiac preganglionic neurons, suggesting the effect was dependent on Ca2+ influx but not 
on Ca2+ release from internal stores. Using selective inhibitors of plasmalemmal Ca2+ 
channels we show that Ca2+ entry in response to nesfatin-1 occurs largely through P/Q-type 
Ca2+ channels, while the N- and L-types have no significant contribution. In hypothalamic 
neurons, in addition to the P/Q-type Ca2+ current, we found a contribution of the L-type 
Ca2+ current to nesfatin-1-induced response (Brailoiu et al. 2007). However, the Ca2+ 
current in cardiac parasympathetic neurons of nucleus ambiguus is mediated nearly entirely 
by P/Q channels (Irnaten et al. 2003). Similar to nesfatin-1, urocortin 3 also activates P/Q 
Ca2+ channels in nucleus ambiguus neurons (Chitravanshi et al. 2012, Brailoiu et al. 2012).
A valuable finding of this study is that nesfatin-1 induced dose-dependent membrane 
depolarization of cardiac vagal neurons via a Gi/o-mediated mechanism, pointing to a 
physiological role of nesfatin-1 and its receptor in the nucleus ambiguus. We have 
previously found a good correlation between the membrane potential of nucleus ambiguus 
neurons measured with classical electrophysiological techniques in brainstem slices and 
with voltage-sensor dyes in cultured nucleus ambiguus neurons (Brailoiu et al. 2009). 
Brailoiu et al. Page 8
J Neurochem. Author manuscript; available in PMC 2014 December 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Remarkably, nesfatin-1 depolarized NPY and NUCB2 neurons from NTS while producing 
heterogeneous effects (depolarization and hyperpolarization) in GABAergic neurons or 
those expressing MC4 receptors (Mimee et al. 2012). Nesfatin-1-induced depolarization in 
NTS neurons was correlated with an increase in blood pressure and heart rate produced by 
microinjection of the peptide in medial NTS (Mimee et al. 2012). In addition, nesfatin-1 
activates hypothalamic neurons and produces tachycardic and hypertensive response via 
sympathetic activation (Yosten and Samson, 2009).
Nesfatin-1 is synthesized both peripherally and in the central nervous system (Angelone et 
al. 2012, Oh-I et al. 2006) and crosses the blood-brain barrier by nonsaturable mechanisms 
(Pan et al. 2007, Price et al. 2007). Other peptides involved in hypothalamic control of 
appetite, such as orexin-A (Ciriello & de Oliveira 2003), neuropeptide Y (Gray et al. 2004) 
or α-melanocyte stimulating hormone (Chitravanshi et al. 2009) also activate the nucleus 
ambiguus neurons.
Given that activation of cardiac vagal neurons of nucleus ambiguus leads to release of 
acetylcholine to the heart and consequent bradycardia (Mendelowitz 1999) we next carried 
out in vivo studies and examined whether or not microinjection of nesfatin-1 into nucleus 
ambiguus affects the heart rate. Since anesthetics may impair the cardiovascular reflexes by 
acting on nucleus ambiguus neurons (Irnaten et al. 2002a, b) we monitored the heart rate by 
telemetry in conscious, freely moving rats. The biotelemetric measurement permits the 
monitoring of heart rate during the microinjection of a compound to be conducted in a 
stress-free manner. Stress-induced tachycardia is documented to occur as a consequence of 
animal handling (McDouglas et al. 2004). Microinjection of nesfatin-1 in nucleus ambiguus 
elicited bradycardia in conscious, freely moving rats. We also carried out heart rate and 
blood pressure measurements via tail-cuff method and identified a consistent bradycardic 
response elicited by L-glutamate and nesfatin-1 without a change in blood pressure. 
Similarly, previous studies indicated a very good correlation between telemetric and tail-cuff 
measurements of blood pressure and heart rate in rats (Fraser et al. 2001; Feng et al. 2008).
While previous studies indicate a modulatory effect of nesfatin-1 on sympathetic tone at 
central and peripheral levels (Yosten & Samson 2009, Tanida & Mori 2011), our results 
indicate for the first time that nesfatin-1 activates cardiac vagal neurons of nucleus ambiguus 
leading to a decrease in heart rate. Microinjection of nesfatin-1 intracerebroventricular 
(Yosten & Samson 2009; Tanida & Mori 2011) or in the medial NTS increases blood 
pressure and heart rate in conscious or anesthetized rats, supporting multiple sites of action 
for nesfatin-1 in autonomic cardiovascular control. Similarly, other peptides were reported 
to act at multiple levels, to modulate both parasympathetic and sympathetic tone. For 
example, orexins modulate the activity of CVNs of nucleus ambiguus (Dergacheva et al. 
2005) and excite sympathetic neurons of rostral ventrolateral medulla (Huang et al. 2010) 
and of spinal cord (Antunes et al. 2001). In humans, oxytocin increases both sympathetic 
and parasympathetic cardiac activity (Norman et al. 2011). Moreover, oxytocin modulates 
cardiovascular activity by acting on NTS (Michelini, 2001) to facilitate vagal outflow (Higa 
et al. 2002) with implications for exercise-induced tachycardia (Braga et al. 2001). 
Arginine-vasopressin increases the GABAergic inhibitory transmission in nucleus ambiguus 
Brailoiu et al. Page 9
J Neurochem. Author manuscript; available in PMC 2014 December 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(Wang et al. 2002) while acting as an excitatory transmitter in rostral ventrolateral medulla 
(Yang et al. 2001).
These reports indicate that peptides exert their modulatory effects on autonomic 
cardiovascular tone at multiple sites and via multiple mechanisms: recruitment of one 
mechanism or another may be dictated by physiological or pathophysiological conditions. 
Our results further support the complexity of nesfatin-1 signaling in the cardiovascular 
system. Since nesfatin-1 is one of the most potent anorexigenic peptides, further studies are 
needed to clarify whether or not nesfatin-1 plays any role in the bradycardia reported among 
patients suffering from anorexia nervosa (Portilla 2011).
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Figure 1. Nesfatin-1 elevates [Ca2+]i in a dose-dependent manner in cardiac vagal preganglionic 
neurons of nucleus ambiguus
A, Representative recording of increase in [Ca2+]i upon administration of 10−6 M nesfatin-1 
(Nesf-1). B, Comparison of the Ca2+ responses elicited by increasing concentrations of 
nesfatin-1 (10−8, 10−7, 10−6, and 10−5 M); and nesfatin-1 (10−6 M) in the presence of the 
oxytoxin receptor antagonist, L-371,257 or of the antagonist of melanocortin receptors type 
3/4, SHU 9119; *P < 0.05; **P > 0.05.
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Figure 2. Nesfatin-1-induced Ca2+ response is subject to tachyphylaxis
A, Illustration of changes in fura-2 AM fluorescence ratio F340/380, before (basal) and 
during the first and second administration of nesfatin-1 (Nesf-1, 10−6M) in a rhodamine-
labeled cardiac vagal neuron. B, Illustration of changes in F340/380 before (basal) and 
during the administration of nesfatin-1 (10−6 M) and urocortin 3 (Ucn 3, 10−6 M) in a 
rhodamine-labeled cardiac vagal neuron. C, Representative Ca2+ responses of nucleus 
ambiguus neurons to two consecutive administrations of nesfatin (10−6 M) or urocortin 3 
(10−6 M) after nesfatin-1. D, Comparison of the amplitudes of [Ca2+]i elevations produced 
by the first and second application of nesfatin-1 (10−6M), and by urocortin 3 (Ucn 3) after 
nesfatin *P < 0.05.
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Figure 3. Nesfatin-1 activates a Gi/o-coupled receptor
A, Characteristic [Ca2+]i recordings illustrating the responses of cardiac vagal neurons to 
administration of nesfatin-1 in presence of inhibitors of Gi/o- or Gs-dependent signaling 
(pertussis toxin, PTX, 100 nM and cholera toxin, CTX, 100 nM, respectively). B, 
Comparison of the Ca2+ responses elicited by nesfatin-1 application to cardiac preganglionic 
neurons in absence and presence of the indicated inhibitors; *P < 0.05.
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Figure 4. Nesfatin-1 promotes Ca2+ influx through P/Q-type voltage gated Ca2+ channels
A, Typical traces illustrating the Ca2+ responses of nucleus ambiguus neurons to nesfatin-1 
(10−6 M) application in Ca2+-free (top left panel) and Ca2+-containing saline in presence of 
nifedipine (L-type Ca2+ channel blocker, 1μM, top right), -conotoxin GVIA (GVIA, N-type 
Ca2+ channel blocker, 100 nM, bottom left) or ω-conotoxin MVIIC (MVIIC, P/Q-type Ca2+ 
channel blocker, 100 nM, bottom right). B, Comparison of the amplitudes of [Ca2+]i 
increases produced by nesfatin-1 in the indicated conditions; *P < 0.05.
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Figure 5. Nesfatin-1 elicits Gi/o-dependent depolarization of cardiac preganglionic neurons of 
nucleus ambiguus
A, Representative recordings illustrating changes in membrane potential of cardiac vagal 
neurons upon application of nesfatin-1 (10−6M) in absence (left) and presence of Gi/o 
inhibitor pertussis toxin (PTX, 100 nM, right). B, Nesfatin-1 (10−8, 10−7, 10−6 and 10−5 M) 
produces a concentration-dependent depolarization of nucleus ambiguus neurons. The 
response to 10−6M nesfatin-1 is sensitive to Gi/o blockade with PTX (100 nM); P < 0.05 
compared to basal (*) or to 10−6 M nesfatin-1 (***); P> 0.05 (**).
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Figure 6. Microinjection of nesfatin-1 into the nucleus ambiguus elicits bradycardia in conscious 
rats
A, Representative examples of heart rate and blood pressure recordings after microinjection 
of saline, L-glutamate (L-Glu, 5 mM, 50 nl) and nesfatin-1 (Nesf-1, 5 pmol, 50 nl) via 
telemetry (top trace) or tail-cuff method (bottom traces). B, Microinjection of nesfatin-1 
(0.05, 0.5, and 5 pmol) produced a dose-dependent decrease in heart rate. Microinjection of 
L-glutamate (L-Glu, 5 mM, 50 nl) and nesfatin-1 (5 pmol, 50 nl) produced a similar 
decrease in heart rate in rats when tail-cuff method was used as compared to telemetry. *P < 
0.05 as compared to basal heart rate (*) or to the other treatment groups (**); ***P> 0.05 as 
compared to the effect of nesfatin-1 on heart rate monitored via telemetry vs tail-cuff.
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